Synthace offers a no-code life sciences R&D cloud platform that automates experimentation, supports reproducible end-to-end workflows, and enables insight sharing across teams. The platform is used to automate molecular biology and protein purification workflows with sample tracking and barcoding, and customers report increased walkaway time for scientists. Seven of the top 10 global pharmaceutical companies have adopted the platform, and named customers include Syngenta and Wheeler Bio. Synthace has signed five strategic GTM partnerships with lab-equipment suppliers Tecan, SPT Labtech, Repligen, Hamilton and BioTek. Business momentum includes a greater than 225% increase in annual recurring revenue and 180% net revenue retention. The company plans to use new funding to fuel commercial and go-to-market growth, expand access globally, and add senior U.S. leadership (new VPs of marketing and sales). Synthace develops Antha, a cloud software platform and language for biology designed to automate and improve the success rate of biological research and development. The company positions itself as a leader in Computer Aided Biology, encompassing digital capabilities powered by AI for designing, simulating and analysing biological systems and physical capabilities enabled by automation to execute wet-lab experiments. Antha aims to create reproducible, scalable workflows that can be readily edited, shared and automated on labs' existing equipment. Synthace serves customers across pharma, agritech and industrial biotechnology and is building its cell and gene therapy customer base. The company has been recognised by Gartner and the World Economic Forum for its role in enabling the Lab of the Future and Industry 4.0. Synthace plans to use new funding to drive continued product development and accelerate global awareness of its solutions. Synthace builds Antha, an open-source operating system that replaces many manual laboratory processes to accelerate biotechnology research and development. The platform enables biologists to abstract workflows, automate experiments, and build on shared work to speed design and scale-up of biological products. Customers include Dow Agrosciences (first customer, MVP installed in fall 2016), Merck & Co (began using Antha in January 2017), and firms such as GSK, Fujifilm Diosynth and Microsoft. The company positions its product as a software layer that helps develop drugs, crops and biologically manufactured materials more efficiently, and compares its role to companies like Ginkgo or Zymergen while focusing on productizing the technology. The recent financing will fund expansion of an ecosystem of biologists, lab-instrument manufacturers, reagent and consumable suppliers, bio-design and analysis software developers, and cloud providers. Synthace applies synthetic biology technologies to engineer and optimize novel biological systems for the production of specialty chemicals and biological products. The platform is initially focused on specialty chemicals but is applicable across healthcare, energy and agriculture. The company is a spin-out of University College London and is led by CEO Tim Fell. Synthace intends to use new funding to demonstrate production of its first chemical products at scale. After demonstrating scale production, the company plans to form partnerships within the chemicals industry to commercialize those products. It also collaborates with academic partners, including UCL and the University of Manchester, on technology development.

Total raised

$73M

Funding rounds

4

Latest round

Series C

Latest activity

Nov 2021